More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$7.64B
EPS
-2.08
P/E ratio
--
Price to sales
24.53
Dividend yield
--
Beta
2.250385
Previous close
$105.04
Today's open
$106.74
Day's range
$102.82 - $112.24
52 week range
$24.41 - $219.71
show more
CEO
Emily M. Leproust
Employees
278
Headquarters
South San Francisco, CA
Exchange
Nasdaq Global Select
Shares outstanding
68178692
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
Artisan Global Discovery Fund Q3 2026 Portfolio Activity
During the quarter, we initiated new positions in Manhattan Associates, Okta and Clean Harbors. In addition to Twilio, West Pharmaceutical and RBC Bearings, we added to Neptune Insurance, Lattice Semiconductor and Cognex during the quarter. In addition to Modine Manufacturing, we ended our investment campaigns in Monolithic Power Systems and Tradeweb Markets.
Seeking Alpha • 5 hours ago

Twist Bioscience: Long-Term 'Buy' On AI Discovery For Biotech
I believe TWST can, over time, capture more of a customer's R&D budget if initial DNA orders lead to more repeat testing and lab data work. TWST's AI drug discovery is at the heart of my growth bull case. But their diagnostics services also dovetail nicely because they could create additional demand. As customers scale personalized cancer testing, TWST could see more demand for its custom panels.
Seeking Alpha • Nov 16, 2026

Twist Bioscience: 3 Key Takeaways for Long-Term Investors
Fourth-quarter revenue grew 28% year over year to $126.6 million. AI drug discovery revenue reached $59.1 million in fiscal 2026.
The Motley Fool • Nov 12, 2026

This Biotech's Guidance Seemingly Beat Expectations — But A Twist Slammed The Stock
Twist Bioscience stock took a header Thursday on artificial intelligence nuances tied to its fiscal year 2027 guidance.
Investors Business Daily • Nov 12, 2026

Twist Bioscience Q4 Earnings Call Highlights
Twist Bioscience NASDAQ: TWST reported 28% revenue growth and positive adjusted EBITDA for its fiscal fourth quarter, as demand for DNA, proteins and data used in AI drug discovery helped drive a 22% increase in full-year sales.
MarketBeat • Nov 12, 2026

Twist Bioscience Corporation (TWST) Q4 2026 Earnings Call Transcript
Twist Bioscience Corporation (TWST) Q4 2026 Earnings Call Transcript
Seeking Alpha • Nov 12, 2026

Twist Bioscience Announces Fiscal 2026 Fourth Quarter and Full Year Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced financial results and business highlights for the fourth quarter and full year fiscal 2026 ended September 30, 2026. Visit the Events and Presentations page of the Investor Relations section under the “Company” tab at www.twistbioscience.com to view the detailed fiscal fourth quarter and full year 2026 earnings report and the investor presenta.
Business Wire • Nov 12, 2026

Twist Bioscience (TWST) Reports Q4 Loss, Beats Revenue Estimates
Twist Bioscience (TWST) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.45 per share a year ago.
Zacks Investment Research • Nov 12, 2026

Alger Mid Cap 40 ETF Q3 2026 Portfolio Review
Twist Bioscience Corp., Cloudflare Inc., and Repligen Corporation were among the top contributors to performance. We believe Cloudflare's extensive network and expanding product portfolio position it to benefit from rising internet traffic, growing cybersecurity needs, and enterprise adoption of AI. FTAI shares detracted from performance during the quarter despite continued growth in its engine products business and progress on adapting mature aircraft engines for data center power generation.
Seeking Alpha • Nov 12, 2026

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value healthcare company, today announced that a total of 17,681 restricted stock units (“RSUs”) will be granted to 19 recently hired individuals, in each case as an inducement material to their acceptance of employment with Twist. The employment inducement awards will be granted under Twist's Amended and.
Business Wire • Nov 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Twist Bioscience Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.